Newsbenzinga
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
· Published
Article summary
Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.
An excerpt from the original article.
Comments —
Loading comments…